166 related articles for article (PubMed ID: 29491307)
1. An Advanced Well-differentiated Pancreatic Neuroendocrine Carcinoma (NET-G3) Associated with Von Hippel-Lindau Disease.
Miki M; Kawabe K; Igarashi H; Abe T; Ohishi Y; Hashimoto R; Karashima T; Yamasaki I; Inoue K; Ito T; Ogawa Y
Intern Med; 2018 Jul; 57(14):2007-2011. PubMed ID: 29491307
[TBL] [Abstract][Full Text] [Related]
2. Use of sunitinib in a 30-year-old woman with pancreatic neuroendocrine tumors associated with Von Hippel-Lindau syndrome.
Wang W; Jiang CY; Wang HW
J Clin Gastroenterol; 2015 Jan; 49(1):89-90. PubMed ID: 24921213
[No Abstract] [Full Text] [Related]
3. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
Tsimafeyeu I
J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
[TBL] [Abstract][Full Text] [Related]
7. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
Liakakos T; Roukos DH
Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
[No Abstract] [Full Text] [Related]
8. Attainment of a Long-term Favorable Outcome by Sunitinib Treatment for Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Associated with von Hippel-Lindau Disease.
Kobayashi A; Takahashi M; Imai H; Akiyama S; Sugiyama S; Komine K; Saijo K; Takahashi M; Takahashi S; Shirota H; Sato N; Fujishima F; Shuin T; Shimodaira H; Ishioka C
Intern Med; 2016; 55(6):629-34. PubMed ID: 26984080
[TBL] [Abstract][Full Text] [Related]
9. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease.
Jonasch E; McCutcheon IE; Waguespack SG; Wen S; Davis DW; Smith LA; Tannir NM; Gombos DS; Fuller GN; Matin SF
Ann Oncol; 2011 Dec; 22(12):2661-2666. PubMed ID: 22105611
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
11. Sequential Everolimus and Sunitinib Treatment in Pancreatic Metastatic Well-Differentiated Neuroendocrine Tumours Resistant to Prior Treatments.
Angelousi A; Kamp K; Kaltsatou M; O'Toole D; Kaltsas G; de Herder W
Neuroendocrinology; 2017; 105(4):394-402. PubMed ID: 28122378
[TBL] [Abstract][Full Text] [Related]
12. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors.
Jimenez C; Cabanillas ME; Santarpia L; Jonasch E; Kyle KL; Lano EA; Matin SF; Nunez RF; Perrier ND; Phan A; Rich TA; Shah B; Williams MD; Waguespack SG
J Clin Endocrinol Metab; 2009 Feb; 94(2):386-91. PubMed ID: 19017755
[TBL] [Abstract][Full Text] [Related]
13. Targeted Therapies Provide Treatment Options for Poorly Differentiated Pancreatic Neuroendocrine Carcinomas.
Gilabert M; Rho YS; Kavan P
Oncology; 2017; 92(3):170-172. PubMed ID: 27838688
[TBL] [Abstract][Full Text] [Related]
14. Metastatic renal cell carcinoma versus pancreatic neuroendocrine tumor in von Hippel-Lindau disease: treatment with interleukin-2.
Williams C; Walther M
ScientificWorldJournal; 2005 Jan; 5():9-10. PubMed ID: 15674444
[TBL] [Abstract][Full Text] [Related]
15. [Gastroenterological manifestations of von Hippel-Lindau disease - a case report].
Koniusz J; Dąbkowski K; Buczek K; Gomółka A; Starzyńska T
Pol Merkur Lekarski; 2017 Aug; 43(254):66-68. PubMed ID: 28875972
[TBL] [Abstract][Full Text] [Related]
16. Late recurrence after surgical resection of a pancreatic tumor in von Hippel-Lindau disease.
Corleto VD; Cotesta D; Petramala L; Panzuto F; Pagnini C; Masoni L; Verrienti A; Delle Fave G; Filetti S; Letizia C
JOP; 2009 Sep; 10(5):562-5. PubMed ID: 19734639
[TBL] [Abstract][Full Text] [Related]
17. [Pancreatic neuroendocrine tumors and von Hippel-Lindau disease].
Musso C; Paraf F; Petit B; Archambeaud-Mouveroux F; Valleix D; Labrousse F
Ann Pathol; 2000 Mar; 20(2):130-3. PubMed ID: 10740008
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and management of pancreatic neuroendocrine tumor in von Hippel-Lindau disease.
Tamura K; Nishimori I; Ito T; Yamasaki I; Igarashi H; Shuin T
World J Gastroenterol; 2010 Sep; 16(36):4515-8. PubMed ID: 20857520
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic mixed serous neuroendocrine neoplasm with clear cells leading to diagnosis of von Hippel Lindau disease.
Kakkar A; Sharma MC; Yadav R; Panwar R; Mathur SR; Iyer VK; Sahni P
Pathol Res Pract; 2016 Aug; 212(8):747-50. PubMed ID: 27161305
[TBL] [Abstract][Full Text] [Related]
20. Predictive Markers of Response to Everolimus and Sunitinib in Neuroendocrine Tumors.
Martins D; Spada F; Lambrescu I; Rubino M; Cella C; Gibelli B; Grana C; Ribero D; Bertani E; Ravizza D; Bonomo G; Funicelli L; Pisa E; Zerini D; Fazio N;
Target Oncol; 2017 Oct; 12(5):611-622. PubMed ID: 28634872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]